Teleflex Incorporated (NYSE:TFX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $252.50.
A number of research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research note on Monday, December 16th. Truist Financial decreased their price target on Teleflex from $227.00 to $200.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Mizuho dropped their price objective on Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. StockNews.com upgraded shares of Teleflex from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Finally, Royal Bank of Canada decreased their price objective on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st.
Get Our Latest Stock Analysis on Teleflex
Institutional Investors Weigh In On Teleflex
Teleflex Price Performance
TFX stock opened at $174.74 on Thursday. The firm has a market cap of $8.12 billion, a P/E ratio of 34.74, a P/E/G ratio of 1.67 and a beta of 1.16. The firm’s fifty day moving average is $177.41 and its 200 day moving average is $208.26. Teleflex has a 52 week low of $165.62 and a 52 week high of $253.06. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
Featured Articles
- Five stocks we like better than Teleflex
- What is the S&P 500 and How It is Distinct from Other Indexes
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- Learn Technical Analysis Skills to Master the Stock Market
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.